United Therapeutics agreed to pay $140 million to acquire Thymmune Therapeutics, extending its regenerative cell therapy efforts focused on restoring thymic function. The purchase includes an upfront fee plus up to $160 million in milestones, with the near-term program centered on THY-100 for congenital athymia.